Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue

British Journal of Cancer

Volumn 84, Issue 6, 2001, Pages 832-835

  Griggs, J ^a   Hesketh, R ^a   Smith, G A ^a   Brindle, K M ^a   Metcalfe, J C ^a   Thomas, G A ^b   Williams, E D ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Angiogenesis; Combretastatin; Goitre; Hyperplasia; Tumour

Indexed keywords

COMBRETASTATIN A4; THYROTROPIN; TUBULIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GOITER; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; THROMBUS; THYROID HYPERPLASIA;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; STILBENES;

EID: 0035937376     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1653     Document Type: Article

References (19)

1. Magnetic resonance imaging and spectroscopy of combretastatin A(4) prodrug-induced disruption of tumour perfusion and energetic status
2. Synthesis of water-soluble prodrugs of the cytotoxic agent combretastatin A4
3. Growth factors and goitrogenesis
4. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumour vasculature
5. Targeting tumour vasculature: The development of Combretastatin A-4
6. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
7. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
8. Anti-vascular therapy: A new approach to cancer treatment
9. Synthesis of biologically active polyphenolic glycosides (combretastatin and resveratrol series)
10. Comparison of FRTL-5 cell growth in vitro with that of xenotransplanted cells and the thyroid of the recipient mouse
11. Antineoplastic agents 389. New syntheses of the combretastatin A-4 prodrug
12. Antineoplastic agents 291. Isolation and synthesis of combretastatins a-4, a-5, and a-6
13. Antineoplastic agents 393. Synthesis of the trans-isomer of combretastatin A-4 prodrug
14. Stimulation by thyroid-stimulating hormone and Graves' immunoglobulin G of vascular endothelial growth factor mRNA expression in human follicles in vitro and fit mRNA expression in the rat thyroid in vivo
15. Combretastutin A-4 phosphate as a tumour vascular-targeting agent: Early effects in tumours and normal tissues
16. Upregulation of the angiogenic factors PIGF. VEGF and their receptors (Fit-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggests a TSH-dependent paracrine mechanism for goitre hypervascularisation
17. Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function
18. Dissociation of growth and function in the rat thyroid during prolonged goitrogen administration
19. Goitrogen induced thyroid growth in the rat: A quantitative morphometric study